Advanced Biomed (ADVB) EBITDA (2023 - 2026)

Advanced Biomed has reported EBITDA for 4 years, with the latest figure at $1.3 million in Q1 2026.

• Quarterly EBITDA rose 3.08% year-over-year to $1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.3 million (up 206.53% YoY) and the FY2025 annual result came in at -$1.6 million, down 109.83% from the prior year.
• EBITDA fell to $1.3 million in Q1 2026 per ADVB's latest filing, from $8.7 million in the prior quarter.
• Over five years, EBITDA peaked at $8.7 million in Q4 2025 and troughed at -$1.2 million in Q2 2025.
• A 4-year average of $1.4 million and a median of $1.2 million in 2024 frame the typical range for EBITDA.
• The sharpest annual moves came in 2024 and 2025: EBITDA jumped 1124.66% in 2024, then plunged 203.22% in 2025.
• Over 4 years, EBITDA stood at -$145345.0 in 2023, then surged by 1124.66% to $1.5 million in 2024, then soared by 484.01% to $8.7 million in 2025, then sank by 85.26% to $1.3 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered $1.3 million, $8.7 million, and $2.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.